(Total Views: 478)
Posted On: 02/10/2025 9:05:16 AM
Post# of 154863
Re: Crujones1985 #150025
Crujones asked…
Would Cydy be affected by NIH grants being slashed, or would it have minimal impact. The reduction in grants includes previously awarded grants that are still being
If NIH shuts down RECOVER and we don’t get to move forward with Long COVID study, we already have a draft protocol synopsis and lead investigator for our ME/CFS study and will move forward with it ourselves.
“Second, in September, CytoDyn applied to the NIH/RECOVER-TLC group for the potential inclusion of leronlimab in their next round of Long Covid treatment studies. We expect to learn the group’s decision in the next several months. In the meantime, we have paused the launch of our previously announced pilot study in patients with myalgic encephalitis/chronic fatigue syndrome (ME/CFS) since the two conditions (Long Covid and ME/CFS) essentially overlap. If the RECOVER-TLC team decides to move forward with leronlimab, we will formally suspend the ME/CFS study. If the RECOVER-TLC team declines to include leronlimab, we will resume the pursuit of a pilot study in patients with ME/CFS, for which we already have a draft protocol synopsis and lead investigator identified.”
Would Cydy be affected by NIH grants being slashed, or would it have minimal impact. The reduction in grants includes previously awarded grants that are still being
If NIH shuts down RECOVER and we don’t get to move forward with Long COVID study, we already have a draft protocol synopsis and lead investigator for our ME/CFS study and will move forward with it ourselves.
“Second, in September, CytoDyn applied to the NIH/RECOVER-TLC group for the potential inclusion of leronlimab in their next round of Long Covid treatment studies. We expect to learn the group’s decision in the next several months. In the meantime, we have paused the launch of our previously announced pilot study in patients with myalgic encephalitis/chronic fatigue syndrome (ME/CFS) since the two conditions (Long Covid and ME/CFS) essentially overlap. If the RECOVER-TLC team decides to move forward with leronlimab, we will formally suspend the ME/CFS study. If the RECOVER-TLC team declines to include leronlimab, we will resume the pursuit of a pilot study in patients with ME/CFS, for which we already have a draft protocol synopsis and lead investigator identified.”
(6)
(0)
